Celanese presented to attendees of the 41st Annual Meeting & Exposition of the Controlled Release Society (CRS) in Chicago, Illinois, USA., a poster session entitled “Predictive Modeling and Validation of Tamoxifen Release from EVA Copolymers.”
“EVA polymers are well-known as a controlled release drug delivery platform for use with many challenging drug molecules,” said Dr Bin Zhang, Celanese senior chemist. “The Celanese VitalDose brand of EVA copolymers offers full biocompatibility and is well suited to the design of complex release profiles and dosage forms using low temperature melt extrusion technology. This study further demonstrates the versatility of VitalDose EVA, offering predictively-modeled dosage of the key oncology drug Tamoxifen.”
As a unique and established controlled release excipient, EVA was evaluated in the study with selected active pharmaceutical ingredients (APIs). APIs solubility and release profiles were studied using Hansen Solubility Parameter calculations and experimental in vitro elution. The paper demonstrates a method that can be used for initial formulation design for controlled drug delivery from EVA copolymers.